FREISING-WEIHENSTEPHAN, Germany, October 25 /PRNewswire/ -- Freising-Weihenstephan, Germany - October 25th 2006. Pieris AG, a bio-pharmaceutical company developing therapeutic products comprising of Anticalins®, a novel proprietary class of human binding proteins, announced today that it has confirmed the functional antagonistic activity of its lead PRS-050 Anticalin® in vivo, supporting the development of superior biotherapeutics with enhanced penetration into neovascularized tissues.
